Phathom Pharmaceuticals says BDR Pharmaceuticals is suing the FDA over a drug application.

Oct 23, 2026, 5:15 PM ETRulesRead the original at SEC EDGAR

Bad for PHAT

BDR sued the FDA over protection for Phathom's VOQUEZNA, which could let the FDA review generic applications sooner and threaten sales. The FDA still recognizes protection through May 3, 2032, and Phathom plans to defend it, but the suit puts that protection at risk.

PHAT · Phathom Pharmaceuticals, Inc.

AI read · Bad for PHAT

The AI's read

VOQUEZNA's protection helps keep generic copies off the market. If BDR wins, the FDA could consider generic applications sooner, putting future sales at risk. The FDA already recognizes the protection, and Phathom says it will defend it. That protection remains in place, but the lawsuit puts future sales at risk.

Get alerts for PHAT

Follow Phathom Pharmaceuticals, Inc. (PHAT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PHAT

Free on the App Store and Google Play, or on the web.